| Hamza Muhammad Pasha, MD | |
|
790 Concourse Pkwy S Ste 200, Maitland, FL 32751-6114 | |
| (407) 767-6411 | |
| Not Available |
| Full Name | Hamza Muhammad Pasha |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 8 Years |
| Location | 790 Concourse Pkwy S Ste 200, Maitland, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306291273 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0120X | Ophthalmology - Cornea And External Diseases Specialist | 150558 (Florida) | Primary |
| 207W00000X | Ophthalmology | BP10060911 (Texas) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventhealth Orlando | Orlando, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Pediatric Associates, Llc | 2567375561 | 25 |
News Archive
Scientists have identified genetic errors in women with autoimmune diseases that increase the risk of preeclampsia, a potentially life-threatening condition that occurs in 10 percent of all pregnancies.
Stroke disproportionately affects more women than men. It is the third leading cause of death in women in the United States, is a leading cause of disability and affects 55,000 more women than men each year.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.
Health care has much to learn from innovative high-tech companies, but not in the way most people think, according to a Perspective published today in the New England Journal of Medicine and authored by innovation experts from the Perelman School of Medicine and the Wharton School at the University of Pennsylvania. Innovation, they say, can most effectively achieve meaningful outcomes by testing many new ideas quickly, cheaply, and contextually.
› Verified 6 days ago
| Entity Name | Florida Pediatric Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053346718 PECOS PAC ID: 2567375561 Enrollment ID: O20031106000599 |
News Archive
Scientists have identified genetic errors in women with autoimmune diseases that increase the risk of preeclampsia, a potentially life-threatening condition that occurs in 10 percent of all pregnancies.
Stroke disproportionately affects more women than men. It is the third leading cause of death in women in the United States, is a leading cause of disability and affects 55,000 more women than men each year.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.
Health care has much to learn from innovative high-tech companies, but not in the way most people think, according to a Perspective published today in the New England Journal of Medicine and authored by innovation experts from the Perelman School of Medicine and the Wharton School at the University of Pennsylvania. Innovation, they say, can most effectively achieve meaningful outcomes by testing many new ideas quickly, cheaply, and contextually.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hamza Muhammad Pasha, MD 790 Concourse Pkwy S Ste 200, Maitland, FL 32751-6114 Ph: (407) 767-6411 | Hamza Muhammad Pasha, MD 790 Concourse Pkwy S Ste 200, Maitland, FL 32751-6114 Ph: (407) 767-6411 |
News Archive
Scientists have identified genetic errors in women with autoimmune diseases that increase the risk of preeclampsia, a potentially life-threatening condition that occurs in 10 percent of all pregnancies.
Stroke disproportionately affects more women than men. It is the third leading cause of death in women in the United States, is a leading cause of disability and affects 55,000 more women than men each year.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.
Health care has much to learn from innovative high-tech companies, but not in the way most people think, according to a Perspective published today in the New England Journal of Medicine and authored by innovation experts from the Perelman School of Medicine and the Wharton School at the University of Pennsylvania. Innovation, they say, can most effectively achieve meaningful outcomes by testing many new ideas quickly, cheaply, and contextually.
› Verified 6 days ago
Dr. Kris-ann Shanique Humphrey, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 790 Concourse Pkwy S Ste 200, Maitland, FL 32751 Phone: 407-767-6411 | |
Dr. Lynda Z Kleiman, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 790 Concourse Pkwy S Ste 200, Maitland, FL 32751 Phone: 407-767-6411 Fax: 407-767-8160 | |
Dr. Robert S Gold, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 790 Concourse Pkwy S, Suite 200, Maitland, FL 32751 Phone: 407-767-6411 Fax: 407-767-8160 | |
Dr. Jerry N Shuster, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 790 Concourse Pkwy S, Suite 200, Maitland, FL 32751 Phone: 407-767-6411 Fax: 407-767-8160 | |
Dr. David B Auerbach, DO Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 790 Concourse Pkwy S, Suite 200, Maitland, FL 32751 Phone: 407-767-6411 Fax: 407-767-8160 | |
Andrew Aziz, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 331 N Maitland Ave, Ste B2, Maitland, FL 32751 Phone: 407-740-0331 Fax: 407-539-2747 |